New technology tracks role of macrophages in cancer spread

October 26, 2020

Macrophages, cells that help engulf and destroy harmful organisms in the body, tend to be characterized as the Jekyll and Hyde of the immune system.

Macrophages are essential first responders in fighting off infections and marshalling other immune cells to the scene. But they also play a major role in contributing to the growth and metastasis of many cancers, especially breast and pancreatic cancer.

New studies at the Morgridge Institute for Research paint a far less simple picture of macrophages, however. Rather than just "good" and "bad" populations, they find a surprisingly wide range of functionality, and better defining those differences may lead to more effective immunotherapies to fight cancer.

Writing this week in the journal Cancer Research, Morgridge researcher Tiffany Heaster and colleagues describe using a combination of technologies to better reveal macrophage function and behavior. The team applied fluorescence imaging to measure the precise metabolic activity of cells, then combined it with 3D microfluidic technology allowing them to see, in real time, how the cells migrate and what role they play.

Importantly, the technologies helped them identify a distinct population of macrophage cells that migrate very actively toward cancer cells in their model -- ones that may have outsized importance in promoting cancer growth. They used both mouse and human cells in the study and found comparable results, indicating this could be a powerful tool for examining the therapeutic potential of macrophages.

"There seems to be more of a spectrum of macrophage phenotypes, and it's been really hard to get at what these phenotypes look like with standard measures," says Heaster, who is now a senior researcher at Genentech after completing her PhD in biomedical engineering at UW-Madison. "We really need to understand these better before we can target the bad macrophages and promote the good ones."

Today, scientists classify two types of macrophages that operate in the tumor micro-environment, Heaster says. The first, called M1, actively kill cancer cells through methods such as piercing or eating the cells and stimulating secondary immune responses. The second, M2, actively support tumor growth by suppressing immune recognition and promoting blood vessel growth (angiogenesis).

They also appear to be a major culprit in metastasis. "There have been studies that have visualized how macrophages kind of latch on to each other and direct traffic (of cancer cells) toward the vasculature to escape," she says.

Heaster says there is a very small subset of immunotherapies that target macrophages today, but they have limited uses compared to other immune cells, such as T cells, because they are poorly understood.

Heaster conducted the research in the lab of Melissa Skala, a Morgridge investigator and professor of biomedical engineering at UW-Madison. Skala says the key innovation is the convergence of two powerful technologies that give scientists a new way to study cancer. Skala is the lead developer of photonics-based technologies to develop personalized treatment plans for cancer. The microfluidics advances originated in the lab of Dave Beebe, a UW-Madison biomedical engineer and co-author on this project.

"Tiffany's technology is helpful because it provides that single-cell resolution, and it provides spatial information so you can understand how different populations of macrophages are behaving metabolically, and how they're distributed throughout the tumor," Skala says.

Addressing macrophages with immunotherapy would help precisely because they are so diverse and may behave differently from one patient to the next, Skala says.

"It's one piece in a complex puzzle to promote anti-tumor immunity," Skala says. "Right now, most of the focus is on T-cells. But macrophages also orchestrate this anti-tumor immunity, so I think a lot of the therapies that are targeting immune involvement are also affecting macrophages. We're trying to understand how."
-end-
This project was supported by the National Cancer Institute, the National Science Foundation and Stand Up to Cancer.

-- Brian Mattmiller, bmattmiller@morgridge.org

Morgridge Institute for Research

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.